Jun 18, 2019 / 12:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the UNITY Biotechnology UBX0101 Phase I Clinical Trial Results Conference Call. (Operator Instructions) And as a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, UNITY's Chief Financial Officer, Mr. Bob Goeltz. Sir, you may begin.
Robert C. Goeltz - Unity Biotechnology, Inc. - CFO
Thank you, operator. Good morning and thanks, everyone, for joining us. With me today are Keith Leonard, our Chairman and Chief Executive Officer; and Jamie Dananberg, our Chief Medical Officer.
Before we get started, I'd like to remind you that during this conference call UNITY Biotechnology will make certain statements that are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our business plans and objectives and timing and success of our clinical trials. Such forward-looking statements are not guarantees of future performance and therefore, you should not put undue reliance upon them.
UNITY Biotechnology Inc to Discuss the UBX0101 Clinical Data Call Transcript
Jun 18, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers